Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1995 Dec 16;311(7020):1595–1599. doi: 10.1136/bmj.311.7020.1595

Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation.

B A Kiberd 1, K K Jindal 1
PMCID: PMC2551496  PMID: 8555801

Abstract

OBJECTIVE: To examine the conditions necessary to make screening for microalbuminuria in patients with insulin dependent diabetes mellitus cost effective. DESIGN: This economic evaluation compared two strategies designed to prevent the development of end stage renal disease in patients with insulin dependent diabetes with disease for five years. Strategy A, screening for microalbuminuria as currently recommended, was compared with strategy B, a protocol in which patients were screened for hypertension and macroproteinuria. INTERVENTION: Patients identified in both strategies were treated with an angiotensin converting enzyme inhibitor. SETTING: Computer simulation. MAIN OUTCOME MEASURES: Strategy costs and quality adjusted life years (QALYs). RESULTS: The model predicted that strategy A would produce an additional 0.00967 QALYs at a present value cost of $261.53 (1990 US$) per patient (or an incremental cost/QALY of $27,041.69) over strategy B. The incremental cost/QALY for strategy A over B was sensitive to several variables. If the positive predictive value of screening for microalbuminuria (impact of false label and unnecessary treatment) is < 0.72, the effect of treatment to delay progression from microalbuminuria to macroproteinuria is < 1.6 years, the cumulative incidence of diabetic nephropathy falls to < 20%, or > 64% of patients demonstrate hypertension at the onset of microalbuminuria, then the incremental costs/QALY will exceed $75,000. CONCLUSION: Whether microalbuminuria surveillance in this population is cost effective requires more information. Being aware of the costs, recommendation pitfalls, and gaps in our knowledge should help focus our efforts to provide cost effective care to this population.

Full text

PDF
1596

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beck J. R., Pauker S. G., Gottlieb J. E., Klein K., Kassirer J. P. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med. 1982 Dec;73(6):889–897. doi: 10.1016/0002-9343(82)90787-2. [DOI] [PubMed] [Google Scholar]
  2. Bennett P. H., Haffner S., Kasiske B. L., Keane W. F., Mogensen C. E., Parving H. H., Steffes M. W., Striker G. E. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis. 1995 Jan;25(1):107–112. doi: 10.1016/0272-6386(95)90636-3. [DOI] [PubMed] [Google Scholar]
  3. Bojestig M., Arnqvist H. J., Hermansson G., Karlberg B. E., Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med. 1994 Jan 6;330(1):15–18. doi: 10.1056/NEJM199401063300103. [DOI] [PubMed] [Google Scholar]
  4. Borch-Johnsen K., Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) 1987 Jun 27;294(6588):1651–1654. doi: 10.1136/bmj.294.6588.1651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Borch-Johnsen K., Wenzel H., Viberti G. C., Mogensen C. E. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ. 1993 Jun 26;306(6894):1722–1725. doi: 10.1136/bmj.306.6894.1722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cohen D. L., Close C. F., Viberti G. C. The variability of overnight urinary albumin excretion in insulin-dependent diabetic and normal subjects. Diabet Med. 1987 Sep-Oct;4(5):437–440. doi: 10.1111/j.1464-5491.1987.tb00905.x. [DOI] [PubMed] [Google Scholar]
  7. Forsblom C. M., Groop P. H., Ekstrand A., Groop L. C. Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration. BMJ. 1992 Oct 31;305(6861):1051–1053. doi: 10.1136/bmj.305.6861.1051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Froberg D. G., Kane R. L. Methodology for measuring health-state preferences--II: Scaling methods. J Clin Epidemiol. 1989;42(5):459–471. doi: 10.1016/0895-4356(89)90136-4. [DOI] [PubMed] [Google Scholar]
  9. Johnston J., Paterson K. R., O'Reilly D. S. Estimating urinary albumin excretion rate of diabetic patients in clinical practice. BMJ. 1993 Feb 20;306(6876):493–494. doi: 10.1136/bmj.306.6876.493-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kattlove H., Liberati A., Keeler E., Brook R. H. Benefits and costs of screening and treatment for early breast cancer. Development of a basic benefit package. JAMA. 1995 Jan 11;273(2):142–148. [PubMed] [Google Scholar]
  11. Krahn M. D., Mahoney J. E., Eckman M. H., Trachtenberg J., Pauker S. G., Detsky A. S. Screening for prostate cancer. A decision analytic view. JAMA. 1994 Sep 14;272(10):773–780. [PubMed] [Google Scholar]
  12. Krahn M., Naylor C. D., Basinski A. S., Detsky A. S. Comparison of an aggressive (U.S.) and a less aggressive (Canadian) policy for cholesterol screening and treatment. Ann Intern Med. 1991 Aug 15;115(4):248–255. doi: 10.7326/0003-4819-115-4-248. [DOI] [PubMed] [Google Scholar]
  13. Krolewski A. S., Laffel L. M., Krolewski M., Quinn M., Warram J. H. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1995 May 11;332(19):1251–1255. doi: 10.1056/NEJM199505113321902. [DOI] [PubMed] [Google Scholar]
  14. Laupacis A., Feeny D., Detsky A. S., Tugwell P. X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992 Feb 15;146(4):473–481. [PMC free article] [PubMed] [Google Scholar]
  15. Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456–1462. doi: 10.1056/NEJM199311113292004. [DOI] [PubMed] [Google Scholar]
  16. Mangili R., Deferrari G., Di Mario U., Giampietro O., Navalesi R., Nosadini R., Rigamonti G., Spezia R., Crepaldi G. Arterial hypertension and microalbuminuria in IDDM: the Italian Microalbuminuria Study. Diabetologia. 1994 Oct;37(10):1015–1024. doi: 10.1007/BF00400465. [DOI] [PubMed] [Google Scholar]
  17. Mathiesen E. R., Rønn B., Jensen T., Storm B., Deckert T. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes. 1990 Feb;39(2):245–249. doi: 10.2337/diab.39.2.245. [DOI] [PubMed] [Google Scholar]
  18. Mogensen C. E., Christensen C. K. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984 Jul 12;311(2):89–93. doi: 10.1056/NEJM198407123110204. [DOI] [PubMed] [Google Scholar]
  19. Mogensen C. E., Hansen K. W., Sommer S., Klebe J., Christensen C. K., Marshall S., Schmitz A., Pedersen M. M., Christiansen J. S., Pedersen E. B. Microalbuminuria: studies in diabetes, essential hypertension, and renal diseases as compared with the background population. Adv Nephrol Necker Hosp. 1991;20:191–228. [PubMed] [Google Scholar]
  20. Mogensen C. E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed) 1982 Sep 11;285(6343):685–688. doi: 10.1136/bmj.285.6343.685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mogensen C. E., Vestbo E., Poulsen P. L., Christiansen C., Damsgaard E. M., Eiskjaer H., Frøland A., Hansen K. W., Nielsen S., Pedersen M. M. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care. 1995 Apr;18(4):572–581. doi: 10.2337/diacare.18.4.572. [DOI] [PubMed] [Google Scholar]
  22. Nease R. F., Jr, Owens D. K. A method for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines. Med Decis Making. 1994 Oct-Dec;14(4):382–392. doi: 10.1177/0272989X9401400409. [DOI] [PubMed] [Google Scholar]
  23. Parving H. H., Oxenbøll B., Svendsen P. A., Christiansen J. S., Andersen A. R. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol (Copenh) 1982 Aug;100(4):550–555. doi: 10.1530/acta.0.1000550. [DOI] [PubMed] [Google Scholar]
  24. Reichard P., Nilsson B. Y., Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993 Jul 29;329(5):304–309. doi: 10.1056/NEJM199307293290502. [DOI] [PubMed] [Google Scholar]
  25. Viberti G. C., Hill R. D., Jarrett R. J., Argyropoulos A., Mahmud U., Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982 Jun 26;1(8287):1430–1432. doi: 10.1016/s0140-6736(82)92450-3. [DOI] [PubMed] [Google Scholar]
  26. Viberti G., Mogensen C. E., Groop L. C., Pauls J. F. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994 Jan 26;271(4):275–279. [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES